The second batch of the antibody cocktail will be made available by mid-June, Cipla added
Cipla and Roche India have launched Roche India s antibody drug cocktail in India for treating mild to moderate COVID-19 cases. Roche India and Cipla today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla said in a regulatory filing to the stock exchanges.
The second batch of the antibody cocktail will be made available by mid-June, Cipla added.
Umang Vohra, Managing Director and Global CEO, Cipla said, We are guided by our strong sense of responsibility to address unmet patient need and look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country .